Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
229 stopped studies mapped to Breast Carcinoma by Gene Expression Profile and descendants · 97% state a reason
Over the 229 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… | Phase 2 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 6, 2023 | Roswell Park Cancer Institute | Funding ended | Funding |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | N/A | suspended | Dec 14, 2016 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT04803084 | Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment | — | suspended | Mar 17, 2021 | Laura Kennedy | MRI upgrade | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | N/A | withdrawn | Sep 24, 2024 | Scripps Health | no patients were able to be enrolled | Enrollment / accrual |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to… | Phase 1 | suspended | Jan 6, 2023 | National Cancer Institute (NCI) | Other - DLT assessment and phase 2 dose determination | Other (stated, no rule matched) |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast… | Phase 1 / Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | BMS terminated the study | Other (stated, no rule matched) |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2020 | University of Alabama at Birmingham | Unable to recruit for this study. | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT06351332 | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | Phase 1 | terminated | Apr 8, 2024 | Filipa Lynce, MD | Zentalis terminated contract due to concern for toxicity safety from previously reported serious… | Safety / toxicity |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive… | Phase 3 | terminated | Jun 27, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast… | Phase 1 | terminated | Mar 14, 2025 | Calibr, a division of Scripps Research | Business Decision | Sponsor / business decision |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… | Phase 2 | terminated | Feb 25, 2025 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | — | terminated | Nov 13, 2018 | University of Washington | Study closed to accrual after meeting grant enrollment goal, prior to reaching protocol accrual… | Enrollment / accrual |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab,…(ADJUNCT) | Phase 2 | withdrawn | Aug 21, 2025 | MedSIR | The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve… | Safety / toxicity |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT05742269 | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative…(MIMIR-mTNBC) | — | terminated | Feb 23, 2023 | Karolinska University Hospital | Slow patient accrual; decreasing use of IMP. | Enrollment / accrual |
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With… | Phase 1 | withdrawn | Jan 29, 2024 | Rush University Medical Center | Internal operational issues prevented the study site from opening to enrollment. | Enrollment / accrual |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | Phase 2 | terminated | Jan 11, 2019 | Gordon Mills, MD, PhD | loss of funding | Funding |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal…(DISCORDANT) | Phase 3 | withdrawn | Sep 19, 2024 | Danish Breast Cancer Cooperative Group | Lack of funding | Funding |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple…(INTEGRAL) | Phase 2 | terminated | Sep 19, 2019 | The Methodist Hospital Research Institute | Stopping rules met per protocol, trial will be terminated | Other (stated, no rule matched) |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With…(neoMono) | Phase 2 | terminated | Feb 25, 2021 | Palleos Healthcare GmbH | The trial stopped recruitment prematurely after a first planned interim analysis of the first 100… | Efficacy / futility |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2…(ELPIS) | Phase 2 | terminated | Oct 8, 2020 | Fundacio Clinic Barcelona | The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize… | Enrollment / accrual |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2… | Phase 1 | terminated | Sep 23, 2022 | Baptist Health South Florida | Slow enrollment | Enrollment / accrual |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | Phase 2 | terminated | Aug 3, 2021 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast… | Phase 2 | terminated | Jul 21, 2017 | University of Chicago | side effects (rash) | Other (stated, no rule matched) |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in…(TrasTUCAN) | Phase 2 | terminated | Oct 17, 2022 | Spanish Breast Cancer Research Group | The study was closed early due to safety concerns and an unfavorable benefit-risk balance.… | Safety / toxicity |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Phase 2 | terminated | Jul 20, 2023 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced… | Phase 1 | terminated | Oct 18, 2016 | Novartis Pharmaceuticals | The early termination was based on a business decision that FAZ053 would no longer be formulated… | Safety / toxicity |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials